Relmada Therapeutics, Inc. (RLMD) stock
RLMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.85−0.15 (-5.15%)
Close on Nov 18, 2026Market cap $304.54MP/E –Yield –
Relmada Therapeutics gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
No gross profit figures for Relmada Therapeutics
Relmada Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?